Leaman John Harold 4

What Happened

• John Leaman, a director of Traws Pharma, received a grant of derivative awards (stock options) for 14,150 shares on July 9, 2026. The Form 4 reports the acquisition at $0.00 (no cash paid at grant); the award is a grant of options under the company's 2021 Incentive Compensation Plan. The options will vest 100% on the first anniversary of the grant date per the filing footnote.

Key Details

• Transaction date: July 9, 2026
• Transaction type/code: Award/Grant (A) — derivative stock options
• Shares/options granted: 14,150
• Cash paid at grant: $0.00 (granting of options, not a purchase)
• Vesting: 100% vests on the first anniversary of the grant date (per footnote)
• Shares owned after transaction: Not specified in the filing
• Filing date: July 14, 2026 — this appears to be filed one business day late for a Form 4 (deadline is within two business days of the transaction)

Context

• This was an option award, not an immediate purchase or sale; options give the right to buy shares in the future after vesting and exercise. Such awards are common as compensation for directors and do not necessarily indicate immediate buying/selling intent. The footnote confirms the award is governed by the company’s 2021 Incentive Compensation Plan.